
Need professional-grade analysis? Visit stockanalysis.com
$1.08T
23.27
24,006
N/A
Price Chart
Risk-Adjusted Performance
Lupin Limited (LUPIN) Price Performance
Lupin Limited (LUPIN) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at INR2331.80, up 0.40% from the previous close.
Over the past year, LUPIN has traded between a low of INR1889.70 and a high of INR2357.30. The stock has gained 19.9% over this period. It is currently 23.4% above its 52-week low.
Lupin Limited has a market capitalization of $1.08T, with a price-to-earnings ratio of 23.27.
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women's health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Company Info
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
- Country
- India
Financial Metrics
- Revenue (TTM)
- $261.51B
- EBITDA
- $68.56B
- Profit Margin
- 17.76%
- EPS (TTM)
- 101.29
- Book Value
- 429.87
Technical Indicators
- 52 Week High
- ₹2,377.60
- 52 Week Low
- ₹1,855.00
- 50 Day MA
- ₹2,216.07
- 200 Day MA
- ₹2,042.91
- Beta
- 0.31
Valuation
- Trailing P/E
- 23.27
- Forward P/E
- 18.05
- Price/Sales
- 4.12
- Price/Book
- 5.46
- Enterprise Value
- $1.07T